SCYNEXIS, Inc. – Trademark Portfolio
Entity Type: 03
SCYNEXIS, Inc. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 3 trademarks are registered and 3 are pending. Notable registered marks include SCYNEXIS and BREXAFEMME. The owner is based in Jersey City, NJ.
1 Evertrust Plaza, 13th Floor
Jersey City, NJ 07302
Showing of trademarks Trademarks
Trademark Classifications
SCYNEXIS, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does SCYNEXIS, Inc. have?
SCYNEXIS, Inc. has 10 U.S. trademarks filed with the USPTO. Of these, 3 registered, 3 pending, 1 abandoned, 3 cancelled.
What trademark classes does SCYNEXIS, Inc. file in?
SCYNEXIS, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are SCYNEXIS, Inc.'s most well-known trademarks?
SCYNEXIS, Inc.'s registered trademark portfolio includes well-known marks such as SCYNEXIS and BREXAFEMME. These are among 3 currently registered trademarks in the portfolio.
What is SCYNEXIS, Inc.'s trademark registration success rate?
SCYNEXIS, Inc. has a 43% trademark registration rate, with 3 out of 7 resolved applications resulting in successful registration. Currently, 3 applications are pending review.